Intellipharmaceutics International Inc.
IPCIQ
$0.00
$0.000.00%
OTC PK
| 08/31/2023 | 05/31/2023 | 02/28/2023 | 11/30/2022 | 08/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 68.70K | 480.20K | 326.30K | 29.70K | 19.10K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 68.70K | 480.20K | 326.30K | 29.70K | 19.10K |
| Cost of Revenue | 873.70K | -- | -- | -- | -- |
| Gross Profit | -805.00K | 480.20K | 326.30K | 29.70K | 19.10K |
| SG&A Expenses | 193.50K | 93.50K | 138.80K | 349.00K | -292.30K |
| Depreciation & Amortization | 40.60K | 40.50K | 40.70K | 51.60K | 51.50K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.86M | 511.60K | 627.70K | 489.30K | 385.30K |
| Operating Income | -1.79M | -31.40K | -301.40K | -459.60K | -366.20K |
| Income Before Tax | -1.89M | -54.10K | -355.70K | -869.40K | -296.00K |
| Income Tax Expenses | -- | -- | -- | 5.30K | -- |
| Earnings from Continuing Operations | -1.89M | -54.10K | -355.70K | -874.70K | -296.00K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.89M | -54.10K | -355.70K | -874.70K | -296.00K |
| EBIT | -1.79M | -31.40K | -301.40K | -459.60K | -366.20K |
| EBITDA | -1.75M | 9.20K | -260.80K | -394.00K | -314.70K |
| EPS Basic | -0.06 | 0.00 | -0.01 | -0.02 | -0.01 |
| Normalized Basic EPS | -0.04 | 0.00 | -0.01 | -0.01 | -0.01 |
| EPS Diluted | -0.06 | 0.00 | -0.01 | -0.02 | -0.01 |
| Normalized Diluted EPS | -0.04 | 0.00 | -0.01 | -0.01 | -0.01 |
| Average Basic Shares Outstanding | 33.09M | 33.09M | 33.09M | 47.73M | 33.09M |
| Average Diluted Shares Outstanding | 33.09M | 33.09M | 33.09M | 47.73M | 33.09M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |